Bristol-Myers Squibb Co
Change company Symbol lookup
Select an option...
BMY Bristol-Myers Squibb Co
AZN AstraZeneca PLC
ALLE Allegion PLC
INTU Intuit Inc
TSLA Tesla Inc
TWLO Twilio Inc
JHS John Hancock Income Securities Trust
AMRC Ameresco Inc
ET Energy Transfer LP
AHCO Adapthealth Corp
Go

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.

Premarket

Last Trade
Delayed
$55.57
0.16 (0.29%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$55.41
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
3,328

10-day average volume:
16,638,391
3,328

BMY's position in the Pharmaceuticals industry

Industry PeersBMYPFELLYZTSRETA

Summary

Company ProfileBristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical...
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical...
Go to PFE summary
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include...
Go to LLY summary
Zoetis Inc. is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests and precision livestock farming...
Go to ZTS summary
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing...
Go to RETA summary
52-Week Change

VS. INDUSTRY
-10.89%
30.00%
70.76%
40.42%
-37.05%
Market Cap

VS. INDUSTRY
$123.0B
$297.7B
$237.1B
$105.6B
$3.1B
Beta

VS. INDUSTRY
0.6
0.7
0.3
0.6
1.5
Dividend Yield

VS. INDUSTRY
3.54%
2.94%
1.37%
0.45%
--
P/E (TTM, GAAP)

VS. INDUSTRY
--
15.98x
37.86x
53.76x
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$45.5B
$69.3B
$27.8B
$7.6B
$13.7M
Profit Margin

VS. INDUSTRY
-11.84%
27.34%
21.52%
25.98%
-2,021.22%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
2.24%
24.60%
38.35%
--
Revenue Growth (TTM)

VS. INDUSTRY
15.42%
70.47%
19.58%
16.42%
61.78%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.